Cargando…

Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group

Despite improvement of prognosis, older age remains a negative prognostic factor in acute promyelocytic leukemia (APL). Reports on disease characteristics and outcome of older patients are conflicting. We therefore analyzed 91 newly diagnosed APL patients aged 60 years or older (30 % of 305 adults w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lengfelder, Eva, Hanfstein, Benjamin, Haferlach, Claudia, Braess, Jan, Krug, Utz, Spiekermann, Karsten, Haferlach, Torsten, Kreuzer, Karl-Anton, Serve, Hubert, Horst, Heinz A., Schnittger, Susanne, Aul, Carlo, Schultheis, Beate, Erben, Philipp, Schneider, Stephanie, Müller-Tidow, Carsten, Wörmann, Bernhard, Berdel, Wolfgang E., Sauerland, Cristina, Heinecke, Achim, Hehlmann, Rüdiger, Hofmann, Wolf-Karsten, Hiddemann, Wolfgang, Büchner, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3536950/ https://www.ncbi.nlm.nih.gov/pubmed/23090499 http://dx.doi.org/10.1007/s00277-012-1597-9

Ejemplares similares

Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia
por: Rausch, Christian, et al.
Publicado: (2023)

Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia
por: Herold, Tobias, et al.
Publicado: (2020)

Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older
por: Prassek, Victoria V., et al.
Publicado: (2018)

P446: COMPREHENSIVE CHARACTERIZATION OF DIFFERENTIAL GENE EXPRESSION AND ISOFORM USAGE IN SPLICING FACTOR-MUTATED ACUTE MYELOID LEUKEMIA USING LONG-READ SEQUENCING
por: Thieme, Susanne, et al.
Publicado: (2023)

Identification of the Adapter Molecule MTSS1 as a Potential Oncogene-Specific Tumor Suppressor in Acute Myeloid Leukemia
por: Schemionek, Mirle, et al.
Publicado: (2015)

Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learning
por: Eckardt, Jan-Niklas, et al.
Publicado: (2022)

Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles
por: Eckardt, Jan-Niklas, et al.
Publicado: (2023)

Mediation analysis reveals common mechanisms of RUNX1 point mutations and RUNX1/RUNX1T1 fusions influencing survival of patients with acute myeloid leukemia
por: Hornung, Roman, et al.
Publicado: (2018)

The NPM1 Mutation Type Has No Impact on Survival in Cytogenetically Normal AML
por: Pastore, Friederike, et al.
Publicado: (2014)

A clinically applicable gene expression–based score predicts resistance to induction treatment in acute myeloid leukemia
por: Moser, Christian, et al.
Publicado: (2021)

Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification
por: Eckardt, Jan-Niklas, et al.
Publicado: (2023)

A 29-gene and cytogenetic score for the prediction of resistance to induction treatment in acute myeloid leukemia
por: Herold, Tobias, et al.
Publicado: (2018)

Acute myeloid leukemia
por: Haferlach, Torsten
Publicado: (2019)

Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk Prediction
por: Pohlen, Michele, et al.
Publicado: (2016)

Expression of CEBPA is reduced in RUNX1-mutated acute myeloid leukemia
por: Grossmann, V, et al.
Publicado: (2012)

Frequency of hematologic and solid malignancies in the family history of 50 patients with acute myeloid leukemia – a single center analysis
por: Sandner, Anne-Sophie, et al.
Publicado: (2019)

Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia
por: Rothenberg-Thurley, Maja, et al.
Publicado: (2018)

Activating FLT3 Mutants Show Distinct Gain-of-Function Phenotypes In Vitro and a Characteristic Signaling Pathway Profile Associated with Prognosis in Acute Myeloid Leukemia
por: Janke, Hanna, et al.
Publicado: (2014)

Correction: Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk Prediction
por: Pohlen, Michele, et al.
Publicado: (2018)

Clonal heterogeneity of FLT3-ITD detected by high-throughput amplicon sequencing correlates with adverse prognosis in acute myeloid leukemia
por: Schranz, Katrin, et al.
Publicado: (2018)

Minimal Residual Disease Diagnostics and Chimerism in the Post-Transplant Period in Acute Myeloid Leukemia
por: Bacher, Ulrike, et al.
Publicado: (2011)

Advancing leukemia diagnostics: Role of Next Generation Sequencing (NGS) in acute myeloid leukemia
por: Haferlach, Torsten
Publicado: (2020)

Clinical application of whole transcriptome sequencing for the classification of patients with acute lymphoblastic leukemia
por: Walter, Wencke, et al.
Publicado: (2021)

Detection of ABL1 kinase domain mutations in therapy-naïve BCR-ABL1-positive acute lymphoblastic leukemia
por: Baer, Constance, et al.
Publicado: (2021)

Management of elderly patients with acute promyelocytic leukemia: progress and problems
por: Lengfelder, Eva, et al.
Publicado: (2013)

A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy
por: Berdel, Andrew F., et al.
Publicado: (2022)

Early prediction of therapy response in patients with acute myeloid leukemia by nucleosomal DNA fragments
por: Mueller, Susanne, et al.
Publicado: (2006)

The clinical mutatome of core binding factor leukemia
por: Opatz, Sabrina, et al.
Publicado: (2020)

Long-term follow-up of cytogenetically normal CEBPA-mutated AML
por: Pastore, Friederike, et al.
Publicado: (2014)

Feasibility of Azacitidine Added to Standard Chemotherapy in Older Patients with Acute Myeloid Leukemia — A Randomised SAL Pilot Study
por: Krug, Utz, et al.
Publicado: (2012)

BAALC expression: a suitable marker for prognostic risk stratification and detection of residual disease in cytogenetically normal acute myeloid leukemia
por: Weber, S, et al.
Publicado: (2014)

Erufosine, a novel alkylphosphocholine, in acute myeloid leukemia: single activity and combination with other antileukemic drugs
por: Fiegl, Michael, et al.
Publicado: (2007)

Molecular Diagnostics, Targeted Therapy, and the Indication for Allogeneic Stem Cell Transplantation in Acute Lymphoblastic Leukemia
por: Oyekunle, Anthony, et al.
Publicado: (2011)

Gene expression profiling for the diagnosis of acute leukaemia
por: Haferlach, T, et al.
Publicado: (2007)

P457: COMPLEX CARYOTYPE IS AN INDEPENDENT RISK FACTOR IN TP53-MUTATED AML
por: Rausch, Christian, et al.
Publicado: (2023)

P434: MYELODYSPLASIA-RELATED MUTATIONS IN THE NEW ELN CLASSIFICATION: DOES CLONAL SIZE PLAY A ROLE?
por: Rausch, Christian, et al.
Publicado: (2023)

Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia—a phase 3 study
por: Braess, Jan, et al.
Publicado: (2018)

Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia
por: Alachkar, Houda, et al.
Publicado: (2014)

Impact of emerging ACA on survival in chronic myeloid leukemia (CML)
por: Hehlmann, Rüdiger, et al.
Publicado: (2022)

The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers
por: Haferlach, Torsten, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_fofh4svtg3mfef89ldenu8fegl